NCT06673927View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of YZJ-1139 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

November 21, 2018

Study Completion Date

March 8, 2019

Conditions
Insomnia
Interventions
DRUG

YZJ-1139

Single oral dose, 2mg, 5mg, 10mg, 20mg, 40mg, 60mg, 80mg

DRUG

YZJ-1139

Multiple Dosing ，Each oral dose of 10 mg，20 mg，40 mg or 60 mg

DRUG

Placebo

Placebo administration

Trial Locations (1)

Unknown

Beijing Ditan Hospital Capital Medical University, Beijing

All Listed Sponsors
lead

Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

INDUSTRY

NCT06673927 - A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of YZJ-1139 in Healthy Participants | Biotech Hunter | Biotech Hunter